Overview
Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients
Status:
Completed
Completed
Trial end date:
2017-05-01
2017-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to evaluate the safety/tolerability and to explore the efficacy of MT-1303 in subjects with systemic lupus erythematosusPhase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Mitsubishi Tanabe Pharma Corporation
Criteria
Inclusion Criteria:- Diagnosis of SLE based on the American College of Rheumatology (ACR) criteria
- Presence of at least one of the following items: positive anti ds-DNA antibodies, low
complement levels, and so on.
- Stable doses of corticosteroids
Exclusion Criteria:
- Severe active lupus nephritis, neuropsychiatric SLE